22 research outputs found

    Visual Masking: A Reliable Measure for the Assessment of Cognitive Dysfunction in the Elderly?

    Get PDF
    Reliable assessment of cognitive dysfunction in the elderly is a prerequisite for the evaluation of treatment of age-related cognitive decline. Psychophysical thresholds are known to be more reliable than psychometric tests, as assessed by stability of performance in visual masking. A backward (Till & Franklin, 1981) and a forward masking study (Coyne, 1981) were replicated. Thereafter, the same volunteers carried out a backward and forward masking task adapted to minimize noncognitive age-related influences: target and mask duration were individually adjusted to control for reduced eye transmissiveness. Attention was assessed with the electrooculogram; a dependent variable insensitive to sporadic decreases of attention was selected. Test-retest stability in the elderly after 2-4 weeks was r = .97 in backward and r = .86 in forward masking. As Alzheimer's disease mainly affects the cortex, backward masking, which is primarily cortical, may be useful to assess aspects of cognitive dysfunctio

    PSYCHIATRY

    Get PDF
    www,elsevier.com/locate/psychre

    Barriers and opportunities for implementation of a brief psychological intervention for post-ICU mental distress in the primary care setting – results from a qualitative sub-study of the PICTURE trial

    Get PDF

    Visual Masking: A Reliable Measure for the Assessment of Cognitive Dysfunction in the Elderly?

    Get PDF
    Reliable assessment of cognitive dysfunction in the elderly is a prerequisite for the evaluation of treatment of age-related cognitive decline. Psychophysical thresholds are known to be more reliable than psychometric tests, as assessed by stability of performance in visual masking. A backward (Till & Franklin, 1981) and a forward masking study (Coyne, 1981) were replicated. Thereafter, the same volunteers carried out a backward and forward masking task adapted to minimize noncognitive age-related influences: target and mask duration were individually adjusted to control for reduced eye transmissiveness. Attention was assessed with the electrooculogram; a dependent variable insensitive to sporadic decreases of attention was selected. Test-retest stability in the elderly after 2–4 weeks was r = .97 in backward and r = .86 in forward masking. As Alzheimer's disease mainly affects the cortex, backward masking, which is primarily cortical, may be useful to assess aspects of cognitive dysfunction

    Magnetic Seizure Therapy Improves Mood in Refractory Major Depression

    No full text
    This report describes the successful treatment of a patient suffering from an episode of drug-resistant major depression using magnetic seizure therapy (MST). The patient suffered from recurrent major depression since adolescence. MST is a novel brain stimulation method using transcranial magnetic stimulation at convulsive parameters in order to induce therapeutic seizures under general anesthesia in the same setting used for electroconvulsive therapy (ECT). The first use of therapeutic magnetic seizure induction in a psychiatric patient took place at the University Hospital in Bern, Switzerland, in May 2000. Results of a recent randomized, within-subject, double-masked trial comparing ECT and MST in 10 patients indicate that MST appears to have less subjective and objective side effects, is associated with faster recovery of orientation, and is superior to ECT on measures of attention, retrograde amnesia, and category fluency. ECT has an unparalleled and well-documented efficacy in severe depression but is associated with cognitive side effects. MST is currently under study in several centers with respect to its antidepressant efficacy. We report here on the treatment of a patient with refractory major depression (DSM IV-R), who underwent a series of 12 sessions of MST in an inpatient setting. Baseline Hamilton Depression Rating Scale (HRSD-21) of 33 and Beck Depression Inventory (BDI) of 40 decreased to 6 and 11 respectively, 1 week after completion of the MST trial. Measures of cognitive functions support the hypothesis that MST is associated with a less severe profile of cognitive side effects. [99mTc]-HMPAO SPECT studies (baseline and 4 days after the completion of the MST trial) point to a raise of blood flow at baseline in the left fronto-parietal region and the brainstem. Our preliminary data support the prospect of antidepressant efficacy of MST and point to a benign cognitive side-effect profile in a patient suffering from severe treatment-resistant major depression

    High frequency repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral cortex: EEG topography during waking and subsequent sleep.

    No full text
    Repetitive transcranial magnetic stimulation (rTMS) is a novel research tool in neurology and psychiatry. It is currently being evaluated as a conceivable alternative to electroconvulsive therapy for the treatment of mood disorders. Eight healthy young (age range 21-25 years) right-handed men without sleep complaints participated in the study. Two sessions at a 1-week interval, each consisting of an adaptation night (sham stimulation) and an experimental night (rTMS in the left dorsolateral prefrontal cortex or sham stimulation; crossover design), were scheduled. In each subject, 40 trains of 2-s duration of rTMS (inter-train interval 28 s) were applied at a frequency of 20 Hz (i.e. 1600 pulses per session) and at an intensity of 90% of the motor threshold. Stimulations were scheduled 80 min before lights off. The waking EEG was recorded for 10-min intervals approximately 30 min prior to and after the 20-min stimulations, and polysomnographic recordings were obtained during the subsequent sleep episode (23.00-07.00 h). The power spectra of two referential derivations, as well as of bipolar derivations along the antero-posterior axis over the left and right hemispheres, were analyzed. rTMS induced a small reduction of sleep stage 1 (in min and percentage of total sleep time) over the whole night and a small enhancement of sleep stage 4 during the first non-REM sleep episode. Other sleep variables were not affected. rTMS of the left dorsolateral cortex did not alter the topography of EEG power spectra in waking following stimulation, in the all-night sleep EEG, or during the first non-REM sleep episode. Our results indicate that a single session of rTMS using parameters like those used in depression treatment protocols has no detectable side effects with respect to sleep in young healthy males

    Repetitive transcranial magnetic stimulation: a putative add-on treatment for major depression in elderly patients.

    No full text
    Repetitive transcranial magnetic stimulation (rTMS) is a recent putative treatment for affective disorders. Several studies have demonstrated antidepressant effects of rTMS in younger patients; we aimed to assess its effect in older outpatients with treatment-resistant major depression. Twenty-four outpatients (mean age=62 years, S.D.=12) with major depression were randomized for sham or real stimulation and received 10 daily rTMS sessions (20 Hz, 2-s trains, 28-s intertrain intervals, 100% of motor threshold) in addition to the antidepressant medication. For sham stimulation, the coil was tilted 90 degrees. Depression severity was assessed using the Hamilton Depression Rating Scale, the Beck Depression Inventory, items from the NIMH self-rated symptom scale, and a visual analog depression scale. Mini-Mental Status Examination performance, memory, and executive and attentional functions were measured to control for cognitive side effects. Depression ratings revealed significant antidepressant effects within 2 weeks in both sham and real stimulation groups; however, there were no between-group differences. Treatment with rTMS was safe; adverse events were rare and not more prevalent in either group, and cognitive assessment did not show any deterioration. We were unable to demonstrate any additional antidepressant effects of real stimulation in elderly patients with treatment-resistant major depression. Therapeutic effects of rTMS in this clinically challenging patient group remain to be demonstrated
    corecore